1. Home
  2. HRMY vs AI Comparison

HRMY vs AI Comparison

Compare HRMY & AI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

N/A

Current Price

$27.73

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Logo C3.ai Inc.

AI

C3.ai Inc.

N/A

Current Price

$8.87

Market Cap

1.3B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
HRMY
AI
Founded
2017
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.3B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
HRMY
AI
Price
$27.73
$8.87
Analyst Decision
Buy
Hold
Analyst Count
10
14
Target Price
$46.70
$14.82
AVG Volume (30 Days)
1.1M
6.3M
Earning Date
05-18-2026
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
7.97
4.27
EPS
2.71
N/A
Revenue
$868,453,000.00
$389,056,000.00
Revenue This Year
$19.87
N/A
Revenue Next Year
$12.49
N/A
P/E Ratio
$10.62
N/A
Revenue Growth
21.51
25.27
52 Week Low
$25.52
$7.72
52 Week High
$40.87
$30.24

Technical Indicators

Market Signals
Indicator
HRMY
AI
Relative Strength Index (RSI) 30.66 38.22
Support Level $27.66 $7.72
Resistance Level $38.91 $9.58
Average True Range (ATR) 1.25 0.57
MACD 0.08 0.08
Stochastic Oscillator 54.02 38.15

Price Performance

Historical Comparison
HRMY
AI

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About AI C3.ai Inc.

C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications: C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications: and C3 Generative AI, which combines the utility of large language models. Geographically the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.

Share on Social Networks: